This is a working overview of AOD-9604, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-03 and is reviewed periodically as new material appears.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
==== Physiological effects ==== Angiotensin II exhibits endocrine, autocrine/paracrine, and intracrine functions. It promotes aldosterone release from the adrenal cortex, as well as arginine vasopressin release from the posterior pituitary. It acts directly upon the proximal tubules of the kidney to regulate water and Na+ reabsorption, promoting reabsorption at very low concentrations while increasingly inhibiting reabsorption with increasing concentrations. In the proximal tubule, it promotes Na+ reabsorption and H+ excretion (which is coupled to bicarbonate reabsorption) by the Na+/H+ exchanger. It causes venous and arterial vasoconstriction by a Gq alpha subunit-coupled receptor upon vascular smooth muscle cells (with downstream IP3-dependent mechanism causing a rise in intracellular Ca2+ to effect smooth muscle excitation-contraction coupling), thus acting to increase blood pressure.
{\displaystyle {\begin{cases}\rho {\dfrac {\partial \mathbf {u} }{\partial t}}+\rho (\mathbf {u} \cdot \nabla )\mathbf {u} -\nabla \cdot {\boldsymbol {\sigma }}(\mathbf {u} ,p)=\mathbf {f} &{\text{ in }}\Omega \times (0,T)\\\nabla \cdot \mathbf {u} =0&{\text{ in }}\Omega \times (0,T)\\\mathbf {u} =\mathbf {g} &{\text{ on }}\Gamma _{D}\times (0,T)\\{\boldsymbol {\sigma }}(\mathbf {u} ,p){\hat {\mathbf {n} }}=\mathbf {h} &{\text{ on }}\Gamma _{N}\times (0,T)\\\mathbf {u} (0)=\mathbf {u} _{0}&{\text{ in }}\Omega \times \{0\}\end{cases}}}
During the flight Cooper reported that he could see roads, rivers, small villages, and even individual houses if the lighting and background conditions were right. This was later confirmed by the two-person Gemini crews (which included Cooper). Cooper slept intermittently the next six hours, during orbits 10 through 13. He woke from time to time and took more pictures, taped status reports, and kept adjusting his spacesuit temperature control which kept getting too hot or too cold. On his fourteenth orbit, Cooper took an assessment of the spacecraft condition. The oxygen supply was sufficient. The peroxide fuel for attitude control was 69 percent in the automatic tank and 95 percent in the manual one. On the fifteenth orbit, he spent most of the time calibrating equipment and synchronizing clocks. When he entered night on the sixteenth orbit, Cooper pitched the spacecraft to slowly follow the plane of the ecliptic. Through the spacecraft window he viewed the zodiacal light and night airglow layer. He took pictures of these two "dim light" phenomena from Zanzibar, across the Earth's nightside, to Canton Island. The pictures were later found to have been overexposed, but they still contained valuable data. Cooper obtained photographs of North Africa, the Arabian peninsula, and eastern India, Burma, and the Himalaya region, as well as a few images of the Pacific and Indian Ocean.
Sources: en.wikipedia.org
== Side effects == The side effects of flutamide are sex-dependent. In men, a variety of side effects related to androgen deprivation may occur, the most common being gynecomastia and breast tenderness. Others include hot flashes, decreased muscle mass, decreased bone mass and an associated increased risk of fractures, depression, and sexual dysfunction including reduced libido and erectile dysfunction. In women, flutamide is, generally, relatively well tolerated, and does not interfere with ovulation. The only common side effect of flutamide in women is dry skin (75%), which can be attributed to a reduction of androgen-mediated sebum production. General side effects that may occur in either sex include dizziness, lack of appetite, gastrointestinal side effects such as nausea, vomiting, and diarrhea, a greenish-bluish discoloration of the urine, and hepatic changes. Because flutamide is a pure antiandrogen, unlike steroidal antiandrogens like cyproterone acetate and megestrol acetate (which additionally possess progestogenic activity), it does not appear to have a risk of cardiovascular side effects (e.g., thromboembolism) or fluid retention.
=== Treatment === To treat the food, it is exposed to a radioactive source for a set period of time to achieve a desired dose. Radiation may be emitted by a radioactive substance, or by X-ray and electron beam accelerators. Special precautions are taken to ensure the food stuffs never come in contact with the radioactive substances and that the personnel and the environment are protected from radiation exposure. Irradiation treatments are typically classified by dose (high, medium, and low), but are sometimes classified by the effects of the treatment (radappertisation, radicidation and radurisation). Food irradiation is sometimes referred to as "cold pasteurisation" or "electronic pasteurisation" because ionising the food does not heat it to high temperatures during the process, and the effect is similar to pasteurisation. The term "cold pasteurisation" is controversial because the term may be used to disguise the fact that the food has been irradiated, and pasteurisation and irradiation are fundamentally different processes.
Plastination is a technique or process used in anatomy to preserve bodies or body parts, first developed by Gunther von Hagens in 1977. The water and fat are replaced by certain plastics, yielding specimens that can be touched, do not smell or decay, and even retain most properties of the original sample.
Any single cycle is longer than 90 days, as long as the individual is at least one year post menarche. The cycle is generally shorter than 21 days or longer than 45 days, as long as the individual is at least one year post menarche. The cycle is generally longer than 35 days, as long as the individual is at least three years post menarche. Amenorrhea which is not due to another underlying cause, as long as the individual is at least 15 years old or at least 3 years post thelarche. Biochemical androgen excess in PMOS is assessed using total and free testosterone. Accurate measurement requires tandem mass spectrometry assays, as direct free testosterone tests are not reliable. Interpretation is based on laboratory reference ranges. Hormonal contraception can interfere with hormone levels, so a withdrawal period of at least three months with alternative contraception may be needed. Severely elevated androgen levels may indicate other conditions.
Sources: en.wikipedia.org
The N-terminal amino group and the C-terminal carboxylic acid can also be used as a site specific site by conjugation with aldehyde functional polymers. The techniques used to form first generation PEG derivatives are generally reacting the PEG polymer with a group that is reactive with hydroxyl groups, typically anhydrides, acid chlorides, chloroformates and carbonates. In the second generation PEGylation chemistry more efficient functional groups such as aldehyde, esters, amides etc. are made available for conjugation. As applications of PEGylation have become more and more advanced and sophisticated, there has been an increase in need for heterobifunctional PEGs for conjugation. These heterobifunctional PEGs are very useful in linking two entities, where a hydrophilic, flexible and biocompatible spacer is needed. Preferred end groups for heterobifunctional PEGs are maleimide, vinyl sulfones, pyridyl disulfide, amine, carboxylic acids and NHS esters. Third-generation pegylation agents, where the polymer has been branched, Y-shaped or comb-shaped are available and show reduced viscosity and lack of organ accumulation. Recently also enzymatic approaches of PEGylation have been developed, thus further expanding the conjugation tools. PEG-protein conjugates obtained by enzymatic methods are already in clinical use, for example: Lipegfilgrastim, Rebinyn, Esperoct.
== Analysis == Analyzing and monitoring the ion milling process is crucial for achieving desired outcomes and ensuring the quality of the results. There are many techniques and instruments that view key parameters during ion milling.
Food packaging is created through the use of a wide variety of plastics and metals, papers, and glass materials. Recycling these products differs from the act of literally reusing them because the recycling process has its own algorithm, which includes collecting, sourcing, processing, manufacturing and marketing these products. According to the Environmental Protection Agency of the United States, the recycling rate has been steadily on the rise, with data reporting that, in 2018, the recycling rate of generated packaging and containers was 53.9 percent. Recycling rates for glass and metal packaging fluctuate considerably based on regional infrastructure, collection methods, and public engagement. In the European Union, glass packaging attains an average recycling rate of approximately 80%. Conversely, the United States exhibits a lower glass recycling rate of roughly 31%, mainly due to contamination and inadequate sorting capabilities. Metal packaging, especially aluminum and steel, typically has superior recycling efficiency. In the EU, aluminum beverage cans achieve recycling rates of approximately 76%. Both materials exhibit superior recycling rates and quality in comparison to plastic and paper. The product's quality and safety are the package's most important responsibility. However, there have been growing demands for packaging to be designed, manufactured, consumed, and recycled in a more sustainable fashion due to the increasing pollution connected with packaging and food waste.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.